Oncology

Level of Evidence (LoE) 1A for all gene expression assays in early ER+ HER2- breast cancer We are pleased to share the latest insights from the ESMO Clinical Practice Guideline for the diagnosis, treatment, and follow-up of early breast cancer, particularly focusing on the significance of genomic testing in estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative

Prospective long-term and real-world data Two prospective real-world studies presented at SABCS show EndoPredict accurately guides decisions on chemotherapy in ER+, HER2- breast cancer. During the San Antonio Breast Cancer Symposium (SABCS) on 6-10 December 2022, new prospective long-term and real-world outcome data were presented from two studies on the EndoPredict Breast Cancer Prognostic Test,

we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.

New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy, regardless of nodal status. 31st August 2022 Myriad Genetics’ EndoPredict Breast Cancer Prognostic Test significantly predicted distant recurrence in premenopausal women with ER+, HER2- early-stage breast cancer, according to a newly published study

Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making We are pleased to announce new data from the prospective EXET trial involving EndoPredict, our prognostic and predictive test for ER positive, HER2 negative early-stage breast cancer. Presented in an abstract at the recent 2022 ASCO Annual Meeting, lead